@misc{indiciae25b152e46e6c,
  title = {GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment},
  author = {Nuermberger, E. and Martinez, M. S. and Sanz, O. and Urones, B. and Esquivias, J. and Soni, H. and Tasneen, R. and Tyagi, S. and Li, S.-Y. and Converse, P. J. and Boshoff, H. I. and Robertson, G. T. and Besra, G. and Abrahams, K. A. and Upton, A. and Mdluli, K. and Boyle, G. W. and Turner, S. and Fotouhi, N. and Cammack, N. C. and Siles, J. M. and Alonso, M. and Excribano, J. and Lelievre, J. and Perez-Herran, E. M. and Bates, R. H. and Maher-Edwards, G. X. and Barros-Aguirre, D. and Ballell, L. and Jimenez, E. N.},
  year = {2022},
  doi = {10.1101/2022.02.04.479214},
  url = {https://www.biorxiv.org/content/10.1101/2022.02.04.479214v1},
  note = {Source identifier: 10.1101/2022.02.04.479214}
}